CNS Summit
Boca Raton, Florida
8-11 October 2015
The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Battery (MCCB) is described as the “gold standard” by members of the Psychiatry Division of the US FDA and the European Medicines Agency. The psychometrics of the MCCB have been increasingly well established. However, the magnitude and predictors of improvement in sequential assessments with placebo treatment is unknown.